Cyclerion Therapeutics, Inc. (CYCN) Earnings Call Transcripts

Cyclerion Therapeutics, Inc.'s Latest Earnings Call - April 1, 2026

In the first quarter of 2026, Cyclerion Therapeutics announced a merger agreement with Korsana Biosciences, which is expected to significantly alter its operational landscape. The merger, an all-stock transaction, will result in Cyclerion shareholders owning approximately 1.5% of the combined entity, while Korsana's shareholders will hold about 98.5%. The merger is expected to close in Q3 2026 and is supported by a $380 million private placement to fund Korsana's pipeline, particularly its lead program KRSA-028, which targets Alzheimer's disease. Management emphasized that the combined cash position will provide a runway into 2029, facilitating key clinical milestones for KRSA-028 expected in 2027.

Reported metrics

Guidance from management

Management expects the merger to close in Q3 2026, subject to shareholder approvals. They also indicated that the combined cash position will support the KRSA-028 program through key clinical milestones expected in 2027.

What analysts pressed on

Analysts expressed concerns about the significant dilution of Cyclerion's existing shareholders, as they will only retain 1.5% ownership post-merger. There are also questions regarding the execution risk associated with the ambitious timelines for KRSA-028's clinical development.

Main topics on the call

• Merger Agreement — Cyclerion announced a merger with Korsana Biosciences, which will result in Cyclerion shareholders owning approximately 1.5% of the combined company. Management stated, "We believe this is the best path forward for Cycle...
• Funding and Cash Position — The merger is supported by a $380 million private placement, ensuring a cash runway into 2029. This funding is crucial for advancing Korsana's KRSA-028 program through key clinical milestones expected in 2027.
• KRSA-028 Development — Korsana's lead program, KRSA-028, is positioned as a potentially best-in-class therapy for Alzheimer's disease. Management highlighted that "KRSA-028 has best-in-class potential" and will initiate clinical development by...
• Clinical Milestones — The company expects to achieve key derisking readouts from healthy volunteers by mid-2027 and interim proof-of-concept data in Alzheimer's patients by the end of 2027. This timeline is critical for investor confidence.

Read the full Cyclerion Therapeutics, Inc. transcript (April 1, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 11 Cyclerion Therapeutics, Inc. earnings call transcripts on record, spanning January 15, 2020 to April 1, 2026. Based on this history, Cyclerion Therapeutics, Inc. reports semi-annually. The most recent call on file is dated April 1, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CYCN

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

11

First call

January 15, 2020

Most recent

April 1, 2026

Reporting cadence

semi-annually